Enhertu Way More Effective Than Kadcyla as 2nd Tx for HER2+ MBC
Enhertu Dramatically More Effective Than Kadcyla as Second Treatment for Metastatic HER2-Positive Breast Cancer
September 22, 2021
Enhertu more than doubled the 12-month progression-free survival rate than Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated. Read more...